EPI N06

Drug Profile

EPI N06

Alternative Names: EPI-N06

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator EpiPharm AG
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Malignant melanoma; Nevus

Most Recent Events

  • 11 Apr 2016 Phase-I/II development is ongoing in Switzerland
  • 07 Jan 2016 EPI N06 is available for licensing as of 07 Jan 2016. http://www.epipharm.ch/
  • 01 Jan 2014 Phase-I/II clinical trials in Malignant melanoma (Prevention) in Switzerland (Topical) prior to January 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top